Total medical devices industry M&A deals worth $7.4bn were announced in North America in April 2021, led by $5bn merger of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 207.5% over the previous month of $2.41bn and a rise of 1.5% when compared with the last 12-month average of $7.3bn.

North America held an 80.81% share of the global medical devices industry M&A deal value that totalled $9.17bn in April 2021. With an 80.81% share and deals worth $7.41bn, the US was the top country in North America’s M&A deal value across medical devices industry.

In terms of M&A deal activity, North America recorded 25 deals during April 2021, marking a decrease of 3.85% over the previous month and a flat growth over the 12-month average. The US recorded 23 deals during the month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

North America medical devices industry M&A deals in April 2021: Top deals

The top five medical devices industry M&A deals accounted for 98.4% of the overall value during April 2021.

The combined value of the top five medical devices deals stood at $7.29bn, against the overall value of $7.4bn recorded for the month.

The top five medical devices industry M&A deals of April 2021 tracked by GlobalData were:

1) The $5bn merger of CA Healthcare Acquisition and LumiraDx

2) The $1.8bn acquisition of Luminex by DiaSorin

3) InVitae’s $200m acquisition of Genosity

4) The $187m acquisition of Better Therapeutics by Mountain Crest AcquisitionII

5) The merger of D8 and Vicarious Surgical for $102.15m.